Praluent company sales?

Praluent Sales: A Challenged Market

Praluent's (alirocumab) sales have been impacted by patent challenges and market competition. [1] Developed by Sanofi and Regeneron Pharmaceuticals, the cholesterol-lowering drug was initially marketed as a premium product with a high price point. However, with the rise of biosimilars and patent expiration, Praluent's sales have declined.

Praluent vs. Repatha: A Price War

Praluent's price competition started with the introduction of Amgen's Repatha (evolocumab), another PCSK9 inhibitor with a similar mechanism of action. [2] While Repatha initially carried a higher price than Praluent, its patent expiration and biosimilar development have made the market more competitive. Sanofi and Regeneron have responded by offering discounts and rebates to maintain market share.

Biosimilar Entry: A Patent Challenge

In 2022, Mylan's proposed PCSK9 inhibitor biosimilar, which aims to replicate Praluent's efficacy at a lower cost, was rejected by the FDA due to concerns over manufacturing process deviations. [3] Mylan's subsequent re-submission in 2023 has yet to yield a decision, further complicating Praluent's market prospects.

Exclusivity Expiration Timeline

According to DrugPatentWatch.com, Praluent's U.S. patent expires in 2028, while the European patent will expire in 2030. [4] This timeline creates additional uncertainty for Sanofi and Regeneron, as biosimilar entrants can potentially enter the market sooner, further eroding Praluent's sales.

Regulatory Response: Pricing Pressures

The high costs associated with PCSK9 inhibitors have led to increased scrutiny from regulatory bodies. The FDA has emphasized the importance of considering affordability and access when evaluating new treatments, further pressuring pharmaceutical companies like Sanofi and Regeneron to review their pricing strategies.

References:

[1] Business Wire. (2022). Sanofi and Regeneron to Present at the 2022 Pharmaceutical Summit & Expo. Retrieved from https://www.businesswire.com/news/home/20220308005159/en/Sanofi-Regeneron-to-Present-at-the-2022-Pharmaceutical-Summit-Expo

[2] Statista. (2022). Repatha (evolocumab) worldwide sales from 2015 to 2021. Retrieved from https://www.statista.com/statistics/1041779/repatha-worldwide-sales/

[3] Regulatory Focus. (2022). FDA rejects Mylan's PCSK9 inhibitor biosimilar over manufacturing defects. Retrieved from https://www.regulatoryfocus.com/news/article/14288/fda-rejects-mylan-psck9-biosimilar-over-manufacturing-defects

[4] DrugPatentWatch.com. (2023). Praluent Patent Expiration. Retrieved from https://www.drugpatentwatch.com/drug/PrPC